Premium
TCV116 Ameliorates Asthma Features in Murine Allergic Asthma Model
Author(s) -
Son SoEun,
Kim MiJeong,
Im DongSoon
Publication year - 2019
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.2019.33.1_supplement.681.3
Subject(s) - irbesartan , ovalbumin , degranulation , bronchoconstriction , bronchoalveolar lavage , asthma , angiotensin ii , immunology , medicine , in vivo , allergic inflammation , pharmacology , inflammation , receptor , lung , immune system , endocrinology , biology , microbiology and biotechnology , blood pressure
Background Several studies have reported on the expression of the type I angiotensin II receptor in human lung tissues. In severe acute attacks of asthma, the renin‐angiotensin system is activated by elevated plasma concentrations of renin and angiotensin II. Furthermore, angiotensin II potentiates methacholine‐induced bronchoconstriction in patients with mild asthma. However, the in vivo anti‐allergic effect of type I angiotensin II receptor antagonists has been poorly evaluated. We aimed to investigate effect of TCV116, an antagonist of the type I angiotensin II receptor on allergic asthma. METHODS To elucidate whether TCV116 lactone has beneficial effects on allergic asthma, anti‐asthma effects were studied using female Balb/c mice and rat RBL‐2H3 mast cells. Antigeninduced degranulation was measured in vitro by measuring b‐hexosaminidase activity. A murine ovalbumin‐induced allergic asthma model was used to test the in vivo efficacy of TCV116. RESULTS It was observed that while TCV116 inhibited the antigen‐induced degranulation in rat RBL‐2H3 mast cells. Administration of TCV116 and irbesartan decreased the number of immune cells in the bronchoalveolar lavage fluid and reduced the expression of Th2 (IL‐4, IL‐5, and IL‐13) and Th1 cytokines (IL‐2 and IFN‐g) in the lung tissues of mice with ovalbumin‐induced allergic asthma. Histological studies revealed that TCV116 and irbesartan reduced inflammation and mucin production in the lungs. CONCLUSION The present findings provide evidence that TCV116 and irbesartan could have potential applications as anti‐allergic agents. This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .